The maintenance of a Buy rating suggests continued confidence in Adicet Bio's potential, but the significant reduction in the price target from $19 to $8 indicates a more cautious outlook on the company's near-term performance. This could lead to a negative short-term impact on the stock price as investors adjust their expectations.